Share your opinion and gain insight from other stock traders and investors. FlexShopper Stock: Small Price, Big Upside ... finance.yahoo.com. And within the M Industry, it might further be delineated into the X Industry group called Banks Northeast. Investors in Akebia Therapeutics, Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 15, 2021 $5.00 Call had some of the highest implied volatility of all equity options today. Google Finance provides real-time market quotes, international exchanges, up-to-date financial news, and analytics to help you make more informed trading and investment decisions. This compares to loss of $0.28 per share a year ago. ... Yahoo Finance UK 'The virus has taken off': Alarming study says 45,000 people get COVID every day in England. The move came on solid volume too with far more shares changing hands than in a normal session. At Yahoo Finance, you get free stock quotes, the latest news, portfolio management resources, international market data, social interaction and mortgage rates to help you manage your financial life. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Investors in Akebia Therapeutics, Inc. AKBA need to pay close attention to the stock based on moves in the options market lately. Akebia Therapeutics, Inc.'s (NASDAQ:AKBA): Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal … As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA). Puedes cambiar tus opciones en cualquier momento visitando Tus controles de privacidad. finance.yahoo.com - November 5 at 11:41 PM: Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates finance.yahoo.com - November 5 at 1:40 PM: Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates finance.yahoo.com - November 5 at 8:40 AM Search query This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.39 to $3.11 in the past one-month time frame. Make 2021 your best (financial) year yet with Yahoo Finance's free daily newsletter. © 2021 Verizon Media. QQQ 310.88. On average, analysts expected the company's net loss per share to be $0.40. Security Date/Time Rebate Rate Fee Rate Shares Available; AKEBIA THERAPEUTICS INC AKBA: 2021-03-08 22:15:03 UTC-0.1874: 0.2574: 2000000: AKEBIA THERAPEUTICS INC AKBA This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. View AKBA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. This quarterly report represents an earnings surprise of … Get the latest Akebia Therapeutics Inc (AKBA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA). DOW 32,297.02. Nosotros y nuestros socios almacenaremos y/o accederemos a la información de tu dispositivo mediante el uso de cookies y tecnologías similares, a fin de mostrar anuncios y contenido personalizados, evaluar anuncios y contenido, obtener datos sobre la audiencia y desarrollar el producto. Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.23. These figures are adjusted for non-recurring items. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -82.61% and -21.20%, respectively, for the quarter ended September 2020. But should shareholders be worried about its use of debt? AKBA Stock Summary. finance.yahoo.com Nov 12, 2020 8:40 am Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their Estimates finance.yahoo.com Nov 7, 2020 7:18 am Is (AKBA) Outperforming Other Medical Stocks This Year? NZ business & finance news, stock quotes, currency information and blogs Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately. Of note is the ratio of Akebia Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 22.54% of US stocks have a lower such ratio. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 6 newly-hired employees options to purchase an aggregate of 27,000 shares of Akebia's common stock on October 30, 2020, as inducements material to each … Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Para permitir a Verizon Media y a nuestros socios procesar tus datos personales, selecciona 'Acepto', o selecciona 'Gestionar ajustes' para obtener más información y para gestionar tus opciones. Para obtener más información sobre cómo utilizamos tu información, consulta nuestra Política de privacidad y la Política de cookies. As with many other companies Akebia Therapeutics, Inc. (NASDAQ:AKBA) makes use of debt. The latest economy, property, and money news, tips and advice: straight to your inbox. Like an eagle, the share price soared 132% in that time. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. On the bottom line, Akebia Therapeutics reported a net loss of $87 million -- $0.60 per share -- compared to the net loss and net loss per share of $94.5 million and $0.79 respectively that it recorded during the fourth quarter of the previous fiscal year. Tip: Try a valid symbol or a specific company name for relevant results, NasdaqGM - NasdaqGM Real Time Price. Información sobre tu dispositivo y conexión a Internet, incluida tu dirección IP, Actividad de navegación y búsqueda al utilizar sitios web y aplicaciones de Verizon Media. Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. Akebia Therapeutics, Inc. (AKBA) Share your opinion and gain insight from other stock traders and investors. All rights reserved. AKBA closed up 8.11 percent on Tuesday, March 9, 2021, on 64 percent of normal volume. Yahoo News UK. Yahoo forma parte de Verizon Media. The Zacks rating relies solely on a company's changing earnings picture. Looking more specifically, AKBA belongs to the Medical - Drugs industry, a group that includes 170 individual stocks and currently sits at #58 in the Zacks Industry Rank. Currency in USD, Trade prices are not sourced from all markets. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Yahoo News. Akebia Therapeutics, Inc. AKBA was a big mover last session, as the company saw its shares rise nearly 7% on the day. The stock has moved higher by 55% in the past month, while it is also above its 20 Day SMA too. While Akebia Therapeutics, Inc. (NASDAQ:AKBA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 15% in the last quarter.Despite this, the stock is a strong performer over the last year, no doubt about that. Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussions in Yahoo Finance's forum. The stock has moved higher by 55% in the past month, while it is also above its 20 Day SMA too. Get the latest Akebia Therapeutics, Inc. (AKBA) stock news and headlines to help you in your trading and investment decisions.